Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBT Margin (2020 - 2023)

Historic EBT Margin for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to 9279.8%.

  • Gain Therapeutics' EBT Margin fell 20119500.0% to 9279.8% in Q1 2023 from the same period last year, while for Dec 2023 it was 40735.22%, marking a year-over-year decrease of 282464500.0%. This contributed to the annual value of 40735.22% for FY2023, which is 282464500.0% down from last year.
  • Latest data reveals that Gain Therapeutics reported EBT Margin of 9279.8% as of Q1 2023, which was down 20119500.0% from 5337.72% recorded in Q2 2022.
  • In the past 5 years, Gain Therapeutics' EBT Margin ranged from a high of 3984.43% in Q2 2021 and a low of 46440.84% during Q1 2021
  • In the last 4 years, Gain Therapeutics' EBT Margin had a median value of 8735.52% in 2020 and averaged 13089.99%.
  • As far as peak fluctuations go, Gain Therapeutics' EBT Margin crashed by -377053300bps in 2021, and later skyrocketed by 391730000bps in 2022.
  • Over the past 4 years, Gain Therapeutics' EBT Margin (Quarter) stood at 18131.62% in 2020, then soared by 59bps to 7471.25% in 2021, then grew by 29bps to 5337.72% in 2022, then crashed by -74bps to 9279.8% in 2023.
  • Its EBT Margin stands at 9279.8% for Q1 2023, versus 5337.72% for Q2 2022 and 7267.84% for Q1 2022.